Universal reference book for medicines
Product name: CARDIONATE В® (CARDIONATE)

Active substance: meldonium

Type: A drug that improves the metabolism and energy supply of tissues

Manufacturer: NIZHFARM (Russia) manufactured by MAKIZ-PHARMA (Russia)
Composition, form of production and packaging
Capsules
hard gelatinous, size 1, white;
the contents of the capsules are a crystalline powder of white or almost white color with a faint odor; The powder is hygroscopic, it is allowed to clump.
1 caps.

meldonia dihydrate * 250 mg,

which corresponds to the content of meldonia 200.5 mg

Auxiliary substances: potato starch, silicon dioxide colloid (aerosil), calcium stearate.

The composition of the shell capsules: gelatin, titanium dioxide.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings cellular planimetric (4) - packs cardboard.
10 pieces.
- packings cellular planimetric (10) - packs cardboard.
100 pieces.
- polymer cans (1) - packs of cardboard.
Capsules hard gelatinous, size в„–00, with a white body and a pink lid;
the contents of the capsules are a crystalline powder of white or almost white color with a faint odor; The powder is hygroscopic, it is allowed to clump.
1 caps.

meldonia dihydrate * 500 mg,

which corresponds to the content of meldonia 401 mg

Auxiliary substances: potato starch, silicon dioxide colloid (aerosil), calcium stearate.

The composition of the capsule shell: gelatin, titanium dioxide, dye azorubin.

10 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings cellular planimetric (4) - packs cardboard.
* - trimethylhydrazinium propionate dihydrate (in terms of dihydrate without adsorbed moisture).

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2014.

PHARMACHOLOGIC EFFECT

A drug that improves the metabolism and energy supply of tissues, a synthetic analogue of gamma-butyrobetaine.
Inhibits gamma-butyrobetaine hydroxynase, reduces synthesis of carnitine and transport of long-chain fatty acids through cell walls, prevents the accumulation of activated forms of unoxidized fatty acids - acylcarnitine and acylcoenzyme derivatives - in the cells.
Cardioprotector, normalizing the metabolism of the myocardium.
Under conditions of ischemia, it restores the equilibrium of the processes of oxygen delivery and its consumption in cells, prevents the violation of ATP transport; simultaneously, it activates glycolysis, which proceeds without additional consumption of oxygen. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is synthesized intensively. The mechanism of action determines the variety of its pharmacological effects: increasing efficiency, reducing the symptoms of mental and physical overstrain, the activation of tissue and humoral immunity, cardioprotective action. In the case of acute ischemic damage to the myocardium, it slows the formation of the necrotic zone, shortens the rehabilitation period.
With heart failure increases myocardial contractility, increases exercise tolerance, reduces the incidence of angina attacks.
In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of the ischemic site. Effective in the case of vascular and dystrophic pathology of the fundus. Characteristic is also a tonic effect on the central nervous system, the elimination of functional disorders of somatic and autonomic nervous systems in patients with chronic alcoholism with withdrawal syndrome.
PHARMACOKINETICS

Suction

After oral administration, it is rapidly absorbed from the digestive tract, C max in the blood plasma is reached after 1-2 hours. Bioavailability is 78%.

Metabolism and excretion

Metabolized in the body with the formation of two major metabolites, which are excreted by the kidneys.
T 1/2 for oral administration depends on the dose and is 3-6 hours.
INDICATIONS

- reduced working capacity;

- Physical overstrain (including athletes);

- Postoperative period to accelerate rehabilitation;

- in the combined therapy of IHD (angina pectoris), chronic heart failure, cardialgia against the background of dyshormonal myocardial dystrophy;

- withdrawal alcohol syndrome (in combination with specific therapy);

- disorders of cerebral circulation (stroke, cerebrovascular insufficiency).

DOSING MODE

In view of the possible development of an exciting effect, it is recommended to apply in the morning.

With a decrease in working capacity and physical overstrain (including athletes), the interior is administered 250 mg 4 times / day.
The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks.
Athletes are appointed inside by 0.5-1 g 2 times / day before training.
The duration of the course in the preparatory period is 14-21 days, during the competition - 10-14 days.
With stable angina , 250 mg are administered 3 times / day for the first 3-4 days, then 250 mg 3 times / day 2 times / week.

With cardialgia against the background of dyshormonal myocardial dystrophy - 250 mg 2 times / day (morning and evening).
The course of treatment is 12 days.
With chronic alcoholism - 500 mg 4 times / day.
The course of treatment is 7-10 days.
For chronic disorders of cerebral circulation - 0.5-1 g / day, preferably in the morning.
The course of treatment is 2-3 weeks.
Capsules swallow whole, washed down with water.

SIDE EFFECT

From the cardiovascular system: rarely - tachycardia, lowering blood pressure.

Allergic reactions: rarely - redness, rashes, itching, swelling.

Other: rarely - dyspepsia, agitation.

CONTRAINDICATIONS

- Increase in intracranial pressure (with violation of venous outflow, intracranial tumors);

- age under 18 years (efficiency and safety not established);

- Hypersensitivity to the components of the drug.

With caution should apply the drug in diseases of the liver and / or kidney.

PREGNANCY AND LACTATION

The safety of the drug during pregnancy is not proven.
To avoid possible adverse effects on the fetus, Cardionate В® should not be administered during pregnancy.
It is not known whether a drug with human milk is excreted in humans.
If you need to use the drug during lactation, breastfeeding should be discontinued.
APPLICATION FOR FUNCTIONS OF THE LIVER

With caution apply the drug for a long time in patients with chronic kidney disease.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

With caution should be used in cases of liver disease.

APPLICATION FOR CHILDREN

Contraindication: age under 18 years (efficacy and safety not established).

SPECIAL INSTRUCTIONS

With caution apply the drug for a long time in patients with chronic liver and kidney diseases.

Use in Pediatrics

There is insufficient data on the use of Cardionata in children.

Impact on the ability to drive vehicles and manage mechanisms

There is no evidence of adverse effects of the drug on the rate of psychomotor reactions.

OVERDOSE

Cases of overdose Cardionata are unknown.
The drug is low in toxicity and does not cause side effects, which are dangerous for the health of patients.
DRUG INTERACTION

Strengthens the action of coronary dilatation drugs, some hypotensive drugs, cardiac glycosides.

You can combine with antianginal drugs, anticoagulants and antiaggregants, antiarrhythmics, diuretics, bronchodilators.

In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive agents and peripheral vasodilators.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

List B. The drug should be stored out of reach of children, dry place at a temperature of no higher than 25 В° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!